PTGX
Protagonist Therapeutics, Inc.NASDAQHealthcare$103.78+0.11%ClosedMarket Cap: $6.62B
As of 2026-04-06
Valuation
P/E (TTM)
—
PEG
—
P/B
10.64
P/S
142.67
EV/EBITDA
-45.05
DCF Value
$-8.63
FCF Yield
0.9%
Div Yield
0.0%
Margins & Returns
Gross Margin
99.2%
Operating Margin
-343.6%
Net Margin
-282.8%
ROE
-19.9%
ROA
-19.4%
ROIC
-25.2%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q4 2025 | $7.4M | 94.9% | $-50.4M | $-44.4M | $-0.69 | — |
| FY 2025 | $46.0M | 97.3% | $-158.1M | $-130.1M | $-2.05 | — |
| Q3 2025 | $4.7M | 100.0% | $-46.4M | $-39.3M | $-0.62 | — |
| Q2 2025 | $5.5M | 100.0% | $-42.0M | $-34.8M | $-0.55 | — |
| Q1 2025 | $28.3M | 100.0% | $-19.3M | $-11.7M | $-0.19 | — |
| Q4 2024 | $170.6M | 100.0% | $126.8M | $131.7M | $1.98 | — |
| FY 2024 | $434.4M | 100.0% | $252.8M | $275.2M | $4.23 | — |
| Q3 2024 | $4.7M | 100.0% | $-41.5M | $-33.2M | $-0.54 | — |
| Q2 2024 | $4.2M | 100.0% | $-38.8M | $-30.6M | $-0.50 | — |
| Q1 2024 | $255.0M | 100.0% | $206.3M | $207.3M | $3.26 | — |
| Q4 2023 | $60.0M | 100.0% | $23.0M | $27.3M | $0.44 | — |
| FY 2023 | $60.0M | 100.0% | $-93.7M | $-79.0M | $-1.39 | — |